Press releases
-
4 May 2010 - Paris (France)25th Colloque Médecine et Recherche of the Fondation Ipsen in the series Alzheimer Disease: “Two Faces of Evil: Cancer and Neurodegeneration”
-
4 May 2010 - Paris (France)18th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “Characterizing Consciousness: From Cognition to the Clinic ? »”
-
3 May 2010 - Paris (France)Ipsen’s first quarter 2010 sales
-
29 April 2010 - Paris (France)Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in a key phase III clinical trial
-
27 April 2010 - Paris (France)Ipsen and Invida Enter into a Partnership for the Commercialization of Ipsen’s Specialty Care Drugs in South-East Asia
-
30 March 2010 - Paris (France) and Watertown, Massachusetts (USA)Dicerna Pharmaceuticals and Ipsen enter into an exclusive research collaboration for the development of new therapeutic agents in endocrinology and oncology
-
30 March 2010 - Paris (France)The Fondation Ipsen’s 8th Endocrine Regulation Prize is awarded to Prof. Gilbert Vassart
-
24 March 2010 - Paris (France)Update on Ipsen’s share capital structure
-
23 March 2010 - Paris (France) and Memphis (USA)GTx and Ipsen expand partnership
-
15 March 2010 - Paris (France)Initiation of two phase II studies with Ipsen’s proprietary BIM 23A760 first-in-class chimeric compound in the treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors
Press Conference
2009 Ipsen Annual Report
CONTACT US
Didier Véron
Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Send an e-mail
Pipeline
